BNYMC Group Reduces Stake in Immuron Limited
Company Announcements

BNYMC Group Reduces Stake in Immuron Limited

Immuron Limited (AU:IMC) has released an update.

The Bank of New York Mellon Corporation (BNYMC) Group has reported a change in their substantial holding in Immuron Limited, with their voting power decreasing from 35.22% to 34.21%. The change occurred on August 2, 2024, and is detailed in the company’s recent statutory filings. This shift reflects a slight reduction in BNYMC Group’s influence over the biopharmaceutical company.

For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmuron plans Phase 2 trial for IMM-529 following FDA review
GlobeNewswireImmuron Plans Phase 2 Trial for IMM-529 following FDA review
TipRanks Australian Auto-Generated NewsdeskImmuron’s IMM-529 Eyes Phase 2 Trial for CDI Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App